Skip to main content
SpringerLink
Log in

Multiple Sklerose: Therapie

  • Living reference work entry
  • First Online:
Klinische Neurologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 661 Accesses

Zusammenfassung

Die zurzeit üblichen Therapiestrategien lassen sich in zwei Gruppen einteilen. Zum einen ist dies die symptomatische Therapie, bei der einzelne Krankheitserscheinungen gemildert werden und die sich nicht nur gegen primäre Auswirkungen der multiplen Sklerose (MS), sondern auch gegen sekundäre Folgestörungen richtet. Symptomatische Therapiemaßnahmen tragen ganz wesentlich zur Verbesserung der Lebensqualität und -erwartung bei und werden individuell an die Bedürfnisse angepasst. Die zweite Gruppe macht sich die zunehmende Kenntnis über die Pathogenese der MS zunutze und versucht, in die pathogenetische Kette zumindest ansatzweise einzugreifen und somit kausal zu behandeln. Kausal behandelt wird die MS in Abhängigkeit von der Krankheitsaktivität mit Steroiden im akuten Schub, alternativ bei ausbleibendem Effekt mit Plasmaseparation oder Immunadsorption und immunmodulatorisch oder immunsuppressiv entsprechend der vorliegenden Verlaufsform und ihrer Dynamik. Grundlage der Therapieentscheidung ist dabei aktuell die Unterscheidung zwischen milder/moderater MS und hochaktiver Erkrankung. Es steht eine große Zahl verschiedener Substanzen zur oralen, subkutanen, intramuskulären und intravenösen Applikation zur Verfügung.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Ascherio A, Munger KL, White R, Kochert K, Simon KC, Polman CH, Freedman MS, Hartung HP, Miller DH, Montalban X et al (2014) Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol 71(3):306–314

    Article  Google Scholar 

  • Bartt RE (2006) Multiple sclerosis, Natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr Opin Neurol 19:341–349

    Article  Google Scholar 

  • Beck RW, Cleary PA, Anderson MM et al (1992) A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 326:581–588

    Article  CAS  Google Scholar 

  • Bielekova B, Catalfamo M, Reichert-Scrivner S et al (2006) Regulatory CD56 (bright) natural killer cells mediate immunoregulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 103:5941–5946

    Article  CAS  Google Scholar 

  • Brønnum-Hansen H, Koch-Hendriksen N, Hyllested K et al (1994) Survival of patients with multiple sclerosis in Denmark: A nation-wide, longterm epidemiologic survey. Neurology 44:1901–1907

    Article  CAS  Google Scholar 

  • Burton JM, Kimball S, Vieth R, Bar-Or A, DoschHM CR, Gagne D, D’Souza C, Ursell M, O’Connor P (2010) A phase I/II dose-escalation trial ofvitamin D3 and calcium in multiple sclerosis. Neurology 74(23):1852–1859

    Article  CAS  Google Scholar 

  • Calabresi PA, Giovannoni G, Confavreux C et al (2007) The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 69:1391–1403

    Article  CAS  Google Scholar 

  • Calabresi PA, Kieseier BC, Arnold DL et al (2014) Pegylated Interferon-ß-1a for RRMS (ADVANCE): a randomized phase 3, double-blind study. Lancet Neurol 13(7):657–665

    Article  CAS  Google Scholar 

  • Coles AJ, Wing MG, Molyneux P et al (1999) Monoclonal antibody treatment exposes 3 mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296–304

    Article  CAS  Google Scholar 

  • Coles AJ, Cox A, Le Page E et al (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98–108

    Article  Google Scholar 

  • Coles AJ, Twyman CL, Arnold DL et al (2012) Alemtuzumab for patients with relapsing multiple sclerosis after disease modifying therapy: a randomized controlled phase 3 trial. Lancet 380:1829–1839

    Article  CAS  Google Scholar 

  • Confavreux C, Li DK, Freedman MS et al (2012) Long-term follow-up of a phase-2-study of oral teriflunomide in relapsing MS: safety and efficacy results up to 8.5 years. Mult Scler 18:1278–1289

    Article  CAS  Google Scholar 

  • Cossburn MD, Harding K, Ingram G et al (2013) Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. Neurology 80:55–61

    Article  CAS  Google Scholar 

  • Cree BAC, Lamb S, Morgan K et al (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:55–61

    Article  Google Scholar 

  • Ebers GC, Traboulsee A, Li D et al (2006) Final results from the Interferon-ß-1b 16-year long term follow-up study. Mult Scler 12:666

    Article  Google Scholar 

  • Fawaz L, Mrad MF, Kazan JM, Sayegh S, Akika R, Khoury SJ (2016) Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation. Clin Immunol 166–167:59–71

    Article  Google Scholar 

  • Frohman EM, Racke MK, Raine CS (2006) Multiple sclerosis – the plaque and its pathogenesis. N Engl J Med 354:942–955

    Article  CAS  Google Scholar 

  • Giovannoni G, Comi G, Cook S et al (2010) A placebo-controlled trial for oral cladribine for relapsing multiples sclerosis. NEJM 362:416–426

    Article  CAS  Google Scholar 

  • Gladstone DE, Kenneth W, Zamkoff W et al (2006) High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol 63:1388–1393

    Article  Google Scholar 

  • Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase-3-study of oral BG-12 or glatiramer for relapsing multiple sclerosis. NEJM 367(12):1098

    Article  CAS  Google Scholar 

  • Gold R, Giovannoni G, Selmaj K et al (2013) Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet 381:2167–2175

    Article  CAS  Google Scholar 

  • Goodin DS, Traboulsee A, Knappertz V et al (2012a) Relationship between early clinical characteristics and long-term disablility outcomes: 16 year cohort study of the pivotal Interferon-ß-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry 83:282–287

    Article  Google Scholar 

  • Goodin DS, Reder AT, Ebers GC et al (2012b) Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFN-ß-1b trial. Neurology 78:1315–1322

    Article  CAS  Google Scholar 

  • Goodman AD, Brown TR, Krupp LB et al (2009) Sustained-release oral fampridine in multiple sclerosis : a randomized, double-blind, controlled trial. Lancet 373:732–738

    Article  CAS  Google Scholar 

  • Goodman AD, Brown TR, Edwards KR et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68:494–502

    Article  CAS  Google Scholar 

  • Hartung HP, Gonsette R, König N et al (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, mulitcentre trial. Lancet 360:2018–2025

    Article  Google Scholar 

  • Hauser SL, Weiner HL (2006) Natalizumab: immune effects and implications for therapy. Ann Neurol 59:731–732

    Article  CAS  Google Scholar 

  • Hauser SL, Waubant E, Arnold DL et al (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688

    Article  CAS  Google Scholar 

  • Hauser SL, Bar-Or A, Comi G et al (2016) Ocrelizumab versus Interferon-ß-1a in relapsing multiple sclerosis. NEJM. https://doi.org/10.1056/NEJMoa1601277

    Article  CAS  Google Scholar 

  • Hawker K, O’Connor P, Freedman MS et al (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 66:460–471

    Article  CAS  Google Scholar 

  • IFNB Multiple sclerosis Study Group (1993a) Interferon-ß-1b is effective in relapsing remitting multiple sclerosis I Clinical results. Neurology 43:655–661

    Article  Google Scholar 

  • IFNB Multiple sclerosis Study Group (1993b) Interferon-ß-1b is effective in relapsing remitting multiple sclerosis II MRI analysis results. Neurology 43:662–667

    Article  Google Scholar 

  • Kampman MT, Steffensen LH, Mellgren SI, Jorgensen L (2012) Effect of vitamin D3 supplementation on relapses, disease progression, and measures of function in persons with multiple sclerosis: exploratory outcomes from a double-blind randomised controlled trial. Mult Scler 18(8):1144–1151

    Article  Google Scholar 

  • Kappos L (1998) Placebo-controlled multicentre randomized trial of Interferon-ß-1b in treatment of secondary progressive multiple sclerosis. European Study Group on Interferon-ß-1b in secondary progressive MS. Lancet 352:1491–1497

    Article  CAS  Google Scholar 

  • Kappos L, Weinshenker B, Pozzilli C et al (2004) Interferon-ß-1bin secondary progressive MS: a combined analysis of the two trials. Neurology 63:1779–1787

    Article  CAS  Google Scholar 

  • Kappos L, Bates D, Hartung HP et al (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431–441

    Article  Google Scholar 

  • Kappos L, Li D, Calabresi PA et al (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomized, placebo-controlled, multicentre trial. Lancet 378:779–787

    Article  Google Scholar 

  • Kappos L, Wiendl H, Selmaj K et al (2015) Daclizumab HYP versus Interferon-beta-1a in relapsing multiple sclerosis. NEJM 373:1418–1428

    Article  CAS  Google Scholar 

  • Kappos L, Bar-Or A, Cree BAC et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomized, phase 3 study. Lancet 391:1263–1273

    Article  CAS  Google Scholar 

  • Khan O, for the GALA Study Group et al (2013) Three times weekly glatiramer acetate in relapsing remitting multiple sclerosis. Ann Neurol 73(6):705–713

    Article  CAS  Google Scholar 

  • Kim SH, Huh SY, Lee SJ et al (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110–1117

    Article  Google Scholar 

  • Kumar R (2008) Approved and investigational uses of Modafinil: an evidence-based review. Drugs 68:1803–1839

    Article  CAS  Google Scholar 

  • Kunkel A, Deppe R, Faiss J et al (2009) Psychoedukatives Training für Patienten mit Multipler Sklerose: Inhalte und Evaluation. Poster 669; 82. Kongress der DGN. Aktuelle Neurologie 36(Suppl 2):S172

    Google Scholar 

  • Leist TP, Comi G, Cree BA et al (2014) Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial Lancet Neurol 13(3):257–267

    Article  CAS  Google Scholar 

  • Limsakun T, Menguy-Vacheron F (2010) Pharmacokinetics of oral teriflunomide, a novel oral disease-modifying agent under investigation for the treatment of multiple sclerosis Neurology 74:A415

    Google Scholar 

  • Linker RA, Lee DH, Ryan S et al (2011) Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134:678

    Article  Google Scholar 

  • Littleton ET, Hbart JC, Palace J (2010) Modafinil for multiple sclerosis fatigue: does it work? Clin Neurol Neurosurg 112(1):29–31

    Article  Google Scholar 

  • Lublin F, Miller DH, Freedman MS et al (2016) Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 387:1075–1084

    Article  CAS  Google Scholar 

  • Maccarone M, Maldonado R, Casas M, Henze T, Centonze D (2017) Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others? Expert Rev Clin Pharmacol 10(4):443–455

    Article  Google Scholar 

  • Mashayekhi F, Salehi Z (2016) Administration of vitamin D3 induces CNPase and myelin oligodendrocyte glycoprotein expression in the cerebral cortex of the murine model of cuprizoneinduced demyelination. Folia Neuropathol 54(3):259–264

    Article  CAS  Google Scholar 

  • McCarthy CL, Tuohy O, Compston DA et al (2013) Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology 81:872–876

    Article  CAS  Google Scholar 

  • Mikol DD, Barkhof F, Chang P et al (2008) Comparison of subcutaneous interferon-β-1a with glatirameracetate in patients with relapsing remitting multiple sclerosis (The Rebif vs GlatiramerAcetate in Relapsing MS Disease [REGARD] study) a multicenter, randomized, parallel, open-label trial. Lancet Neurol 7:903–914

    Article  CAS  Google Scholar 

  • Miller DH, Soon D, Fernando KT et al (2007) MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 68:1390–1401

    Article  CAS  Google Scholar 

  • Mills RJ, Yap L, Young CA (2007) Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev (1):CD005029

    Google Scholar 

  • Montalban X, Hauser SL, Kappos L et al (2016) Ocrelizumab versus Placebo in primary progressive multiple sclerosis. NEJM. https://doi.org/10.1056/NEJMoa1606468

    Article  CAS  Google Scholar 

  • Mowry EM, Waubant E, McCulloch CE, Okuda DT, Evangelista AA, Lincoln RR, Gourraud PA, Brenneman D, Owen MC, Qualley P et al (2012) Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 72(2):234–240

    Article  CAS  Google Scholar 

  • Muris AH, Smolders J, Rolf L, Thewissen M, Hupperts R, Damoiseaux J, group Ss (2016) Immune regulatory effects of high dose vitamin D3 supplementation in a randomized controlled trial in relapsing remitting multiple sclerosis patients receiving IFNbeta; the SOLARIUM study. J Neuroimmunol 300:47–56

    Article  CAS  Google Scholar 

  • Neuhaus O, Kieseier BC, Hartung HP (2006) Therapeutic role of mitoxanrone in multiple sclerosis. Pharmacol Ther 109:198–209

    Article  CAS  Google Scholar 

  • Nielsen NM, Munger KL, Koch-Henriksen N, Hougaard DM, Magyari M, Jorgensen KT, Lundqvist M, Simonsen J, Jess T, Cohen A et al (2017) Neonatal vitamin D status and risk of multiple sclerosis: a population based case-control study. Neurology 88(1):44–51

    Article  CAS  Google Scholar 

  • Novotna A, Mares J, Ratcliffe S et al (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18(9):1122–1131

    Article  CAS  Google Scholar 

  • O’Connor P, Comi G, Montalban X et al (2009a) Oral fingolimod (FTY 720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 72:73–79

    Article  Google Scholar 

  • O’Connor P, Filippi M, Arnason B et al (2009b) 250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomized, multicentre study. Lancet Neurol 8:889–897

    Article  Google Scholar 

  • O’Connor PW, Wolinsky JS, Confavreux C et al (2014) Randomized trial of oral teriflunomide in multiples sclerosis with relapses. NEJM 365(14):1293

    Article  Google Scholar 

  • Pakpoor J, Disanto G, Altmann DR et al (2015) No evidence for higher risk of cancer in patients with multiple sclerosis taking cladribine. Neurol Neuroimmunol Neuroinflamm 2:e158. https://doi.org/10.1212/NXI.0000000000000158

    Article  PubMed  PubMed Central  Google Scholar 

  • Panitch H, Miller A, Paty D, Weinshenker B (2004) Interferon-ß-1b in secondary progressive MS : results from a 3-year controlled study. Neurology 63:1788–1795

    Article  Google Scholar 

  • Papadopoulou A, D’Souza M, Kappos L, Yaldizli Ö (2010) Dimethylfumarat for multiple sclerosis. Expert Opin Investig Drugs 19(12):1603–1612

    Article  CAS  Google Scholar 

  • Polman CH, O’Connor PW, Havrdova E et al (2006) A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 354:899–910

    Article  CAS  Google Scholar 

  • Ransohoff RM (2007) Natalizumab for multiple sclerosis. N Engl J Med 356:2622–2629

    Article  CAS  Google Scholar 

  • Reder AT, Ebers GC, Traboulsee A et al (2010) Cross sectional study assessing long-term safety of Interferon-ß-1b for relapsing remitting multiple sclerosis. Neurology 74:1877–1885

    Article  CAS  Google Scholar 

  • Ropper AH (2006) Selective treatment of multiple sclerosis. N Engl J Med 354:965–967

    Article  CAS  Google Scholar 

  • Rudick RA, Stuart WH, Calabresi PA et al (2006) Natalizumab plus Interferon beta – 1a for relapsing multiple sclerosis. N Engl J Med 354:911–923

    Google Scholar 

  • Sandberg L, Bistrom M, Salzer J, Vagberg M, Svenningsson A, Sundstrom P (2016) Vitamin D and axonal injury in multiple sclerosis. Mult Scler 22(8):1027–1031

    Article  CAS  Google Scholar 

  • Schimrigk S, Faiss J, Köhler W et al (2016) Escalation therapy of steroid refractory multiple sclerosis relapse with tryptophan immunadsorption – observational multicenter study with 147 patients. Eur Neurol 75:300–306

    Article  CAS  Google Scholar 

  • Schwab N, Schneider-Hohendorf T, Melzer N, Cutter G, Wiendl H (2017) Natalizumab-associated PML: challenges with incidence, resulting risk, and stratification. Neurology 88(12):1197–1205

    Article  CAS  Google Scholar 

  • Seidel D (1995) MS – Symptomatische Therapie und Rehabilitation. TW Neurol Psychiatr 9:578–582

    Google Scholar 

  • Serra A, Fox RJ (2013) Dimethylfumarate for relapsing multiple sclerosis. Neurol Clin Pract 3(3):249–253

    Article  Google Scholar 

  • Sloka JS, Stefanelli M (2005) The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 11:425–432

    Article  CAS  Google Scholar 

  • Steiner D, Arnold DL, Freedman MS et al (2016) Natalizumab versus placebo in patients with SPMS: results from ASCEND, a multicenter, double-blind, placebo-controlled, randomized phase 3 clinical trial. In: Poster 68th annual meeting American Academy of Neurology, Vancouver

    Google Scholar 

  • Stellmann JP, Krumbholz M, Friede T (2017) Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. JNNP. https://doi.org/10.1136/jnnp-2017-315603

    Article  Google Scholar 

  • Stüve O, Marra CM, Cravens PD et al (2007) Potential risk of progressive multifocal leukoencephalopathy with Natalizumab therapy: possible interventions. Arch Neurol 64:169–176

    Article  Google Scholar 

  • Trebst C, Jarius S, Berthele A et al (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol 261:1–16

    Article  CAS  Google Scholar 

  • Vermersch P, Czlonkowska A, Grimaldi LM et al (2014) Teriflunomide versus subcutaneous interferon-ß-1a in patients with relapsing MS: a randomized controlled phase-3 trial. Mult Scler 20(6):705

    Article  CAS  Google Scholar 

  • Wade DT, Collin C, Stott C, Duncombe P (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16:707–714

    Article  CAS  Google Scholar 

  • Warnke C, Meyer zu Hörste G, Menge T et al (2013) Teriflunomid zur Behandlung der MS. Nervenarzt 84:724

    Article  CAS  Google Scholar 

  • Wolinsky JS, Narayana PA, O’Connor P et al (2007) Glatiramer Acetat in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 61:14–24

    Article  CAS  Google Scholar 

  • Wuest SC, Edwan JH, Martin JF et al (2011) A role for interleukin-2-trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 17:604–609

    Article  CAS  Google Scholar 

  • Zajicek J, Fox P, Sanders H et al (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS-study): multicenter randomised placebo-controlled trial. Lancet 362:1517–1526

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Asklepios Fachklinikum Teupitz, Teupitz, Deutschland

    Jürgen Faiss

Authors
  1. Jürgen Faiss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jürgen Faiss .

Editor information

Editors and Affiliations

  1. Essen, Germany

    Peter Berlit

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Faiss, J. (2019). Multiple Sklerose: Therapie. In: Berlit, P. (eds) Klinische Neurologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44768-0_160-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44768-0_160-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44768-0

  • Online ISBN: 978-3-662-44768-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation